Last updated: October 30, 2026
Trasylol, the brand name for aprotinin, was a high-value antifibrinolytic used to reduce blood loss during open-heart surgery. Its commercial trajectory changed sharply after studies linked the drug to renal failure, myocardial infarction, stroke, and increased mortality. Bayer suspended worldwide marketing in 2007, and regulatory restrictions later limited any potential re-entry. Trasylol has no meaningful remaining patent-exclusivity advantage, no established generic-growth story, and limited commercial value outside tightly controlled cardiac-surgery use.
The drug is a biologically derived polypeptide from bovine lung, but it is regulated principally as a drug rather than as a modern U.S. biologics-license product. Its commercial decline resulted from safety and regulatory action rather than ordinary patent expiry.
What is Trasylol and how did its market develop?
Trasylol is aprotinin, a serine protease inhibitor that blocks plasmin, kallikrein, and related enzymes involved in fibrinolysis and inflammation. It was administered intravenously during cardiopulmonary bypass procedures to reduce perioperative bleeding and transfusion requirements.
| Item |
Details |
| Active ingredient |
Aprotinin |
| Brand |
Trasylol |
| Original developer and marketer |
Bayer |
| Therapeutic class |
Antifibrinolytic; serine protease inhibitor |
| Primary use |
Blood-loss reduction in open-heart surgery |
| Administration |
Intravenous |
| Biological source |
Bovine lung-derived protein |
| U.S. regulatory status |
FDA approval followed by suspension, then restricted availability |
| Principal competitors |
Tranexamic acid and epsilon-aminocaproic acid |
| Commercial status |
Broad commercial market effectively ended after the 2007 withdrawal |
Aprotinin was commercially attractive because cardiac surgery generated a concentrated, high-value hospital market. The drug commanded a premium over older synthetic antifibrinolytics because physicians viewed it as an effective blood-conservation product for complex procedures.
How did Trasylol sales change before and after the 2007 withdrawal?
Trasylol reached peak commercial use before the safety crisis. Public company disclosures and contemporary reporting place annual sales in the low hundreds of millions of euros before withdrawal, with 2006 sales commonly reported at approximately €212 million. The product was one of Bayer’s more significant hospital medicines, although it was not comparable in scale with the company’s largest primary-care and specialty franchises.
The financial trajectory had four stages:
| Period |
Commercial position |
Financial effect |
| Pre-2006 |
Premium cardiac-surgery antifibrinolytic |
Strong hospital sales and high procedural value |
| 2006-2007 |
Safety signals and growing clinical concern |
Demand weakened before formal withdrawal |
| Late 2007 onward |
Worldwide marketing suspension |
Product revenue collapsed |
| 2012 onward |
Restricted regulatory availability in selected settings |
Limited residual demand; no return to former sales levels |
The BART trial, published in 2008, reported higher mortality with aprotinin than with lysine analogues in high-risk cardiac surgery. The study accelerated the shift toward tranexamic acid and epsilon-aminocaproic acid, both of which were less expensive and had broader physician acceptance after the safety controversy. [1]
What regulatory action affected Trasylol?
The FDA issued a public health advisory in November 2007 after reviewing observational studies and clinical data linking aprotinin with serious adverse outcomes. Bayer then suspended marketing of Trasylol worldwide, except for narrowly defined situations. [2]
The FDA later permitted restricted use under a controlled framework. The regulatory position required physicians to reserve aprotinin for patients undergoing cardiopulmonary bypass when the anticipated benefit of reducing blood loss outweighed the potential risks. Use was limited by patient selection, institutional controls, informed consent, and post-market monitoring requirements. [3]
The European regulatory history was also restrictive. European authorities initially recommended suspension and later allowed narrowly controlled use in selected isolated coronary artery bypass grafting procedures. The European position required that aprotinin be used only when blood conservation was clinically necessary and when the expected benefit exceeded the risks. [4]
FDA regulatory status
Trasylol’s regulatory history does not support a conventional relaunch thesis:
- The broad commercial indication was effectively lost after the 2007 action.
- Any later availability depended on controlled, restricted use.
- Hospital adoption became dependent on institutional risk committees and cardiac-surgery protocols.
- The drug faced a materially higher evidentiary burden than tranexamic acid.
- The market lacked the volume and pricing conditions that existed before 2007.
Public U.S. regulatory records should be read in conjunction with the current FDA label and drug-supply status because product availability and labeling can change independently of historical approval status.
What patents protect Trasylol and aprotinin?
No significant live composition-of-matter patent estate is associated with the original Trasylol product. Aprotinin was discovered and commercialized decades ago, placing the core molecule well beyond ordinary U.S. and European patent terms.
| Patent category |
Commercial relevance |
| Aprotinin composition patent |
Expired or commercially irrelevant |
| Original cardiac-surgery method patents |
Expired or unlikely to block entry |
| Intravenous formulation protection |
No meaningful current exclusivity identified |
| Manufacturing patents |
Potential process know-how, but not a broad market barrier |
| Device or delivery patents |
Minimal relevance because the product is an injectable hospital drug |
| Regulatory exclusivity |
No current meaningful exclusivity advantage |
The main intellectual-property risks are therefore not classic patent-blocking risks. They are manufacturing, regulatory, quality, and supply risks.
What formulations are protected by Trasylol patents?
Trasylol was marketed as an injectable solution for intravenous administration. A modern formulation strategy would require control over protein stability, aggregation, sterility, potency, source-material qualification, and cold-chain handling. Those technical requirements can create practical barriers even when patent protection has expired.
A competitor would not need to replicate Bayer’s exact formulation to enter the therapeutic category. A different aprotinin formulation could potentially avoid legacy formulation claims, subject to regulatory equivalence and manufacturing requirements. The stronger barriers are likely to be:
- Validated production of a biologically derived protein.
- Control of bovine-source materials and transmissible-agent risk.
- Batch consistency and impurity control.
- Stability and container-closure validation.
- Clinical evidence supporting the risk-benefit profile.
- Hospital acceptance after the historical safety controversy.
When did Trasylol lose exclusivity?
Trasylol lost practical exclusivity long before the 2007 withdrawal. Aprotinin’s age means the original molecule was not protected by a modern patent term when the product was commercially withdrawn.
The important commercial date was not patent expiry. It was November 2007, when Bayer suspended marketing after the FDA safety action. The product’s value then shifted from an established branded franchise to a restricted, low-volume hospital product with substantial liability exposure.
This distinction matters for generic-launch analysis. A generic manufacturer would not face a meaningful patent thicket, but it would face a weak market opportunity and potentially high clinical-development, pharmacovigilance, and product-liability costs.
Which companies are challenging Trasylol?
No major current Paragraph IV challenge defines the Trasylol market. The molecule’s age, the absence of important live composition patents, and the collapse in demand make a conventional patent challenge commercially unattractive.
The competitive challenge came from alternative antifibrinolytics rather than from branded pharmaceutical competitors.
| Product |
Competitive position |
| Tranexamic acid |
Lower-cost alternative with extensive use in cardiac and other surgical settings |
| Epsilon-aminocaproic acid |
Established lysine analogue used for bleeding control |
| Aprotinin |
Historically potent but burdened by renal, cardiovascular, mortality, and regulatory concerns |
| Blood-conservation protocols |
Cell salvage, surgical hemostasis, transfusion management, and procedural changes reduce demand for drug-based intervention |
Tranexamic acid became the main commercial substitute because it was inexpensive, widely available, and supported by a broad clinical evidence base. The shift reduced the addressable market for aprotinin even where aprotinin remained legally available.
What patent litigation and settlement agreements affected Trasylol?
Trasylol generated substantial product-liability litigation after the safety controversy. Plaintiffs alleged that Bayer failed to adequately disclose risks associated with renal injury, cardiovascular events, stroke, and death. Litigation included U.S. federal multidistrict proceedings and large numbers of individual and coordinated claims.
The legal exposure affected the asset in three ways:
- It increased the cost of continued marketing.
- It reduced Bayer’s incentive to invest in a commercial relaunch.
- It raised the risk profile for any acquirer considering rights, manufacturing, or distribution.
Public reporting described Bayer settlements and litigation reserves involving Trasylol claims, but aggregate settlement figures varied by proceeding, claim category, and reporting period. The liability record remains more commercially important than any surviving patent dispute.
There is no prominent current settlement structure that creates a clear pathway for broad re-commercialization. Any transaction involving the brand, manufacturing rights, or clinical data would require detailed allocation of historical and future product-liability exposure.
How strong is the Trasylol patent estate?
The patent estate is weak as a blocking asset and potentially irrelevant to present-day market value.
| Factor |
Assessment |
| Core molecule protection |
Very weak or expired |
| Formulation protection |
Limited practical relevance |
| Method-of-use protection |
No meaningful current exclusivity expected |
| Manufacturing know-how |
Potentially relevant |
| Regulatory data package |
Historical value, but not a durable exclusivity barrier |
| Litigation leverage |
Low on patent grounds |
| Commercial defensibility |
Dependent on supply, regulatory controls, and clinical positioning |
The strongest residual asset is not patent exclusivity. It is the historical product identity, clinical experience, and potential access to manufacturing knowledge. Those assets have limited value unless a sponsor can establish a narrowly defined clinical need that cannot be met by tranexamic acid or epsilon-aminocaproic acid.
What is the generic launch risk for Trasylol?
Generic entry risk is structurally high because patent barriers are low. Commercial generic-launch probability is a separate question and is substantially lower.
A prospective entrant would face:
- A small and specialized market.
- A regulatory record associated with serious safety concerns.
- Limited physician demand.
- Low expected volume.
- High-quality and manufacturing requirements for a protein product.
- Potential product-liability exposure.
- Competition from inexpensive synthetic alternatives.
- Institutional restrictions on use.
The likely launch model would be a niche hospital product rather than a broad generic campaign. A manufacturer would need a reliable supply chain, a restrictive risk-management strategy, and a clear reimbursement case.
How does Trasylol compare with tranexamic acid?
| Attribute |
Trasylol |
Tranexamic acid |
| Drug type |
Bovine-derived serine protease inhibitor |
Synthetic lysine analogue |
| Main use |
Cardiac-surgery blood-loss reduction |
Broad surgical and bleeding indications |
| Cost position |
Historically premium |
Low-cost generic |
| Safety perception |
Damaged by renal and mortality concerns |
More favorable overall market perception |
| Patent position |
Expired or commercially weak |
Mature generic market |
| Physician adoption |
Restricted and specialized |
Broad |
| Commercial outlook |
Limited niche use |
Durable, diversified demand |
| Entry opportunity |
Low-volume specialty market |
High-volume generic market |
Tranexamic acid has a more resilient market because it is used across cardiac, orthopedic, trauma, obstetric, dental, and other surgical settings. Aprotinin would need a clearly superior outcome in a defined high-risk population to regain share.
What is the revenue outlook for Trasylol?
No credible basis exists for a return to pre-2007 revenue levels. Public company reporting does not establish a current standalone Trasylol revenue stream comparable with its historical sales.
The likely revenue profile is:
- Minimal or no broad branded revenue.
- Intermittent sales in restricted hospital settings.
- Limited geographic availability.
- Low probability of substantial price expansion because alternatives are inexpensive.
- High deduction for pharmacovigilance, liability, and distribution controls.
- Weak strategic value for a large pharmaceutical company.
A relaunch could create value only in a narrow scenario involving a defined clinical niche, favorable comparative evidence, controlled supply, and a liability structure acceptable to the sponsor. Without those conditions, the product is more relevant as a regulatory and litigation case study than as a scalable pharmaceutical asset.
What licensing deals could revive aprotinin?
There is no widely recognized current licensing transaction that has restored Trasylol to broad commercial distribution. A potential licensing deal would need to address four issues:
- Rights to the brand, regulatory file, and clinical data.
- Manufacturing and source-material qualification.
- Historical product-liability allocation.
- Regulatory strategy for restricted use.
The most plausible commercial structure would be a regional hospital-product license or contract-manufacturing arrangement. A global branded relaunch would be difficult to justify because the relevant market is fragmented and the safety record would require extensive education and monitoring.
Key Takeaways
- Trasylol is aprotinin, a bovine-derived antifibrinolytic used in open-heart surgery.
- Historical sales reached approximately €212 million in 2006 before safety-driven withdrawal.
- Bayer suspended worldwide marketing in 2007 after evidence linked aprotinin to serious renal, cardiovascular, and mortality risks.
- Later regulatory access was restricted and did not restore the former commercial market.
- The core patent estate is expired or commercially weak.
- There is no meaningful current Paragraph IV or patent-litigation threat shaping the market.
- Tranexamic acid and epsilon-aminocaproic acid displaced aprotinin in most commercial settings.
- Generic entry is legally feasible but commercially unattractive.
- Manufacturing controls, regulatory restrictions, and product-liability exposure are stronger barriers than patents.
- Trasylol has little prospect of returning to blockbuster economics without new comparative evidence and a narrowly defined clinical indication.
FAQs About Trasylol Market and Financial Outlook
Is Trasylol still sold in the United States?
Broad commercial marketing was withdrawn after the 2007 safety action. Later regulatory pathways permitted restricted use in limited circumstances, but this did not recreate the former commercial market.
Is aprotinin a biologic drug?
Aprotinin is a biologically derived protein drug obtained from bovine lung. It is not generally treated as a modern U.S. biologics-license product in the same manner as monoclonal antibodies or recombinant proteins.
Can a generic company launch aprotinin?
Patent barriers are unlikely to prevent entry, but a sponsor would face regulatory, manufacturing, safety, supply, and liability obstacles. The expected market is too small for a conventional high-volume generic strategy.
Why did hospitals replace Trasylol with tranexamic acid?
Tranexamic acid is less expensive, widely available, and supported by broad clinical use. Aprotinin’s association with kidney injury and mortality materially reduced physician and institutional acceptance.
Does Trasylol have meaningful future licensing value?
Potential value is limited to a specialized regional or controlled-use market. Any transaction would depend more on regulatory positioning, manufacturing capability, and liability allocation than on patent exclusivity.
References
-
Fergusson, D. A., Hébert, P. C., Mazer, C. D., Fremes, S., MacAdams, C., Murkin, J. M., et al. (2008). A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. New England Journal of Medicine, 358(22), 2319-2331. https://doi.org/10.1056/NEJMoa0802395
-
U.S. Food and Drug Administration. (2007). FDA issues public health advisory on Trasylol. FDA Drug Safety Communications.
-
U.S. Food and Drug Administration. (2012). FDA approves limited reintroduction of Trasylol under restricted conditions. FDA drug safety and labeling materials.
-
European Medicines Agency. (2012). European Medicines Agency recommends lifting suspension of aprotinin with restrictions. EMA press and regulatory communications.
-
Bayer AG. (2007). Annual report 2007. Bayer investor-relations publications.
-
Bayer AG. (2006). Annual report 2006. Bayer investor-relations publications.
